Next Phase Newsletter

A venture capital firm founded in 2002 is looking to invest in tech-based digital health and diagnostics companies looking to expand to the Chinese market. The firm primarily invests in European companies, but will consider companies based in the US as well. The firm looks to leverage their connections to China and the Chinese market on behalf of its portfolio companies. The firm looks to invest between $2-10M in companies, taking a 15-30% equity stake. The firm prefers to be a lead investor, taking an active role in their portfolio companies, and will invest in about 2 companies a year, depending on their fund cycle. In cases where The firm does not invest funds, they are also willing to offer consulting services for equity, connecting companies with strategic partners in China.

The firm has an additional partnership model that, instead of direct investment, licenses technologies through a Chinese platform company, acting as a focused distributor for entry into the Chinese market. This is the firm’s alternate investment approach to bringing these technologies to the Chinese market, by utilizing this Chinese platform company to serve as their portfolio company’s representative in China to navigate the regulatory environment and spearhead all of the sales and marketing.

The firm is interested in tech companies that are not consumer focused. The firm looks for companies such as diagnostics tools or AI/machine learning technologies in the healthcare space. The firm has some experience with pathology diagnostic related companies, but is willing to consider other areas as well. The firm prefers to invest in a few companies within the same area, choosing complementary technologies between their portfolio companies. The firm will consider companies with technologies that are in development or in pilot stages.

The firm is an active investor and takes a board seat for every company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of an Europe-headquartered bank invests in early-stage companies in the life science industry among other technologically oriented industries, and is looking to engage in late seed, Series A or Series B rounds. The initial investments typically range from 0.5M to 3M Euros. The firm is open to both leading and co-investing, and prefer to syndicate with other investors. The firm is primarily interested in companies based in Germany, Austria and Switzerland.

The firm is looking for new opportunities in the life science space including therapeutics, diagnostics, medical devices and digital health. The firm is interested in companies from pre-clinical to clinical stages onward, and would like to see some preclinical validations for therapeutics companies or prototypes for medical devices. The firm is opportunistic in terms of sector, subsectors and indications, and is open to considering orphan diseases.

The firm doesn’t have specific requirements for management teams. The firm is open to both leading and co-investing, and prefers to take a board seat when investing larger amounts.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and China invests exclusively in healthcare companies (therapeutics, medical devices, digital health, and healthcare services). The firm typically invests $1-5M (USD) of equity capital with the ability to make follow-on investment. The fund aims to make at least 5 investments per year, but this is not a fixed number. In general, the firm participates in seed, series A and series B funding rounds. The firm looks at companies of all parts of the world and has a strong preference for companies that have market opportunities in the US, Europe and China. The firm’s China office can provide companies with the resources they need for successful market entry in Asian markets.

The firm looks at all sectors pertaining to healthcare, including biotech therapeutics, R&D services, diagnostics, medical devices, and digital health. While the firm’s focus is in early-stage companies, it takes a very opportunistic viewpoint. In therapeutics, the firm will look at products of all stages from pre-clinical to phase III, and is open to all indications. In terms of medical devices, the firm will consider both 510k and PMA devices. In addition, the firm will also consider products that are already on the market.

The firm is open to both public and private companies, and expects them to have an experienced management team with a strong exit strategy. The firm requires a board seat in all portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital arm of a large Spanish investment holding company is actively seeking early-stage investment opportunities. A 100 million euros allocation of the fund is dedicated to life sciences investments, while the rest of the fund will focus on investing in manufacturing and digital technology. The typical size of investment can range from 1 to 5 million euros, but the firm has the capacity to invest more in following investments in portfolio companies. The firm can participate at any stage but with preference for investments in Series A and B rounds, and has invested in more than 30 companies. The firm is willing to both lead and co-invest in companies located in Spain and Portugal, and the firm will only participate as a co-investor in European and North American companies. The firm looks to tailor its services to help and collaborate with portfolio companies to reach key value-added milestones.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics companies. The firm is opportunistic in terms of therapeutic areas. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase I.

The firm will invest in privately held companies only. The firm seeks companies with a full-time management team with expertise, successful track records would be a plus but is not required. The firm takes a board seat in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An Israel-based venture capital firm whose sole LP is the CK Hutchison Holdings group. The group operates the world’s largest international health and beauty retailer. With over 15,700 stores in 25 markets in Europe and Asia. The firm looks to provide a unique stepping stone for successful companies to broaden their global reach. The firm offers partners deep understanding of relevant audiences and a unique opportunity for truly innovative, trail-blazing consumer-related digital health ventures. The firm is looking to invest in digital therapeutics, POC diagnostics, and other dHealth companies from seed stage and beyond. The firm is interested in companies with well defined, relevant products and solutions, preferably with initial validation or proof-of-concept. The firm invests globally, and is flexible to the size of investment, depending on the needs of the company.

Within the digital health and POC diagnostics space, the firm has many areas of interest. These include, but are not limited to, telemedicine, remote monitoring, patient adherence, FemTech and aging. The firm will also invest in digital therapeutics, with no drug-based component, which may require prescription.

The firm has no specific requirements for company and management team, and makes decisions on a case-by-case basis. The firm can lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Based in London, the group is the largest membership-based non-profit organization in the world dedicated to finding a cure and improving life for everyone affected by Parkinson’s disease. The group originally focused on research grants, but is now implementing a venture philanthropy model with an evergreen structure that provides funding to biotech startups from an annual budget called the Virtual Biotech program. For 2019-2024, this program looks to invest about $30M into for-profit early stage biotech companies working on Parkinson’s therapies. The group does look for some type of return, but is extremely flexible with the size and structure of investments, ranging up to about $2M per company/project and may employ convertible notes, rights/options, capped royalties, etc. The group is primarily focused on companies located in North America or Europe and will co-invest with VCs and professional investors.

The group is exclusively focused on therapeutics companies working on drugs for treating/curing Parkinson’s disease. The group will fund projects that are targeting related neurodegenerative diseases that have potential in Parkinson’s or are pursuing Parkinson’s in parallel. Also, the group will invest in assets that are being repurposed for Parkinson’s. The group will invest from discovery up unto Ph. IIa clinical trials.

The group has no strict company or management requirements and will invest in early-stage project as well as established companies. The group may or may not seek a board seat along with investment depending on the stage and needs of the company as well as the level of involvement they look to play in the company’s development.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm headquartered in Paris with offices and partners in San Francisco, New York and London. The firm is investing out of its first, 2015-vintage, $275M fund and makes both seed/venture and growth stage investments ranging from $500k – $20M. The firm typically prefers straight equity investments, but will also consider convertible note financings. The firm has a fairly broad mandate, and invests evenly among enterprise software, fintech, consumer and digital health sectors. The fund’s LPs are large insurance companies, and along with capital, the firm looks to add value by providing portfolio companies direct introductions to these groups to help scale and realize their potential.

The firm plans to have digital health companies make up roughly 25% of its portfolio and will invest in consumer and B2B healthcare IT and tech-enabled health services. It is a requirement that the technology has utility for payers and providers. Some of the firm’s digital health portfolio companies include a behavior change platform that partners with insurers, Accountable Care Organizations (ACO) and Self-insured employers to provide research-based behavioral incentives for members to better manage their chronic conditions.

The firm invests in global early-stage companies with annual revenues under $5M as well as growth stage companies with annual revenues exceeding $5M. The firm will consider pre-revenue companies with strong management teams and previously successful entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.